ADD008

ADD008 is a proprietary, sulfite-free, and heat-stable aqueous formulation of adrenaline (epinephrine) developed by Theravia for the emergency treatment of anaphylaxis. Conventional adrenaline formulations, such as those used in EpiPen, typically require sulfite preservatives (e.g., sodium metabisulfite) to prevent oxidation; however, these sulfites can trigger hypersensitivity reactions in some patients and limit the product's stability at higher temperatures. ADD008 utilizes a novel stabilization technology to provide a sulfite-free alternative that is designed for intramuscular delivery via standard, off-the-shelf auto-injectors. The program is currently in Phase 1 clinical development (NCT05843123), with studies evaluating its pharmacokinetic and pharmacodynamic profile in comparison to established adrenaline auto-injectors like EpiPen and Anapen.